Report cover image

Pharmerging Market by Product (OTC Drugs, Pharmaceuticals), Indication (Cancer & Autoimmune Diseases, Lifestyle Diseases), Distribution - Global Forecast 2024-2030

Publisher 360iResearch
Published Jan 15, 2024
Length 191 Pages
SKU # IRE18448937

Description

Pharmerging Market by Product (OTC Drugs, Pharmaceuticals), Indication (Cancer & Autoimmune Diseases, Lifestyle Diseases), Distribution - Global Forecast 2024-2030


The Pharmerging Market size was estimated at USD 1.53 billion in 2023 and expected to reach USD 1.68 billion in 2024, at a CAGR 9.74% to reach USD 2.94 billion by 2030.

Global Pharmerging Market

FPNV Positioning Matrix

The FPNV Positioning Matrix is pivotal in evaluating the Pharmerging Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Pharmerging Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Key Company Profiles

The report delves into recent significant developments in the Pharmerging Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories Inc., AstraZeneca PLC, Bayer AG, Beckman Coulter, Inc., Bikal Ltd., CSL Behring LLC, Eli Lilly and Company, Farmson Pharmaceutical Gujarat Pvt. Ltd, GlaxoSmithKline PLC, Glenmark Pharmaceuticals Ltd, Johnson and Johnson, Lonza Group AG, Novartis AG, Pfizer, Inc., Rhombus Pharma Private Limited, Röchling Group, SCHOTT AG, Sun Pharmaceutical Industries Ltd., The RSA Group, and ZIM Laboratories Limited.

Market Segmentation & Coverage

This research report categorizes the Pharmerging Market to forecast the revenues and analyze trends in each of the following sub-markets:

Product
OTC Drugs
Pharmaceuticals
Branded Prescription Drugs
Generic Drugs
Indication
Cancer & Autoimmune Diseases
Lifestyle Diseases
Distribution
Clinics
Drug Stores
E-Commerce
Hospitals
Region
Americas
Argentina
Brazil
Canada
Mexico
United States
California
Florida
Illinois
New York
Ohio
Pennsylvania
Texas
Asia-Pacific
Australia
China
India
Indonesia
Japan
Malaysia
Philippines
Singapore
South Korea
Taiwan
Thailand
Vietnam
Europe, Middle East & Africa
Denmark
Egypt
Finland
France
Germany
Israel
Italy
Netherlands
Nigeria
Norway
Poland
Qatar
Russia
Saudi Arabia
South Africa
Spain
Sweden
Switzerland
Turkey
United Arab Emirates
United Kingdom

The report offers valuable insights on the following aspects:

1. Market Penetration: It presents comprehensive information on the market provided by key players.
2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.
3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.
4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.
5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.

The report addresses key questions such as:

1. What is the market size and forecast of the Pharmerging Market?
2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the Pharmerging Market?
3. What are the technology trends and regulatory frameworks in the Pharmerging Market?
4. What is the market share of the leading vendors in the Pharmerging Market?
5. Which modes and strategic moves are suitable for entering the Pharmerging Market?

Note: PDF & Excel + Online Access - 1 Year

Table of Contents

191 Pages
1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Limitations
1.7. Assumptions
1.8. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Pharmerging Market, by Region
5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Growing elderly population and rising burden of chronic diseases worldwide
5.1.1.2. Rising number of private hospitals and healthcare institutes
5.1.1.3. Extensive spending on healthcare globally and growing life expectancy among people
5.1.2. Restraints
5.1.2.1. High cost of research and development and strict price control
5.1.3. Opportunities
5.1.3.1. Potential demand from targeted therapeutics or personalized medicines
5.1.3.2. Emerging adoption of pharmerging in developing economies
5.1.4. Challenges
5.1.4.1. Concerns over IP protection and socio-politics with complex government approval process
5.2. Market Segmentation Analysis
5.3. Market Trend Analysis
5.4. Cumulative Impact of High Inflation
5.5. Porter’s Five Forces Analysis
5.5.1. Threat of New Entrants
5.5.2. Threat of Substitutes
5.5.3. Bargaining Power of Customers
5.5.4. Bargaining Power of Suppliers
5.5.5. Industry Rivalry
5.6. Value Chain & Critical Path Analysis
5.7. Regulatory Framework
6. Pharmerging Market, by Product
6.1. Introduction
6.2. OTC Drugs
6.3. Pharmaceuticals
6.4.1. Branded Prescription Drugs
6.4.2. Generic Drugs
7. Pharmerging Market, by Indication
7.1. Introduction
7.2. Cancer & Autoimmune Diseases
7.3. Lifestyle Diseases
8. Pharmerging Market, by Distribution
8.1. Introduction
8.2. Clinics
8.3. Drug Stores
8.4. E-Commerce
8.5. Hospitals
9. Americas Pharmerging Market
9.1. Introduction
9.2. Argentina
9.3. Brazil
9.4. Canada
9.5. Mexico
9.6. United States
10. Asia-Pacific Pharmerging Market
10.1. Introduction
10.2. Australia
10.3. China
10.4. India
10.5. Indonesia
10.6. Japan
10.7. Malaysia
10.8. Philippines
10.9. Singapore
10.10. South Korea
10.11. Taiwan
10.12. Thailand
10.13. Vietnam
11. Europe, Middle East & Africa Pharmerging Market
11.1. Introduction
11.2. Denmark
11.3. Egypt
11.4. Finland
11.5. France
11.6. Germany
11.7. Israel
11.8. Italy
11.9. Netherlands
11.10. Nigeria
11.11. Norway
11.12. Poland
11.13. Qatar
11.14. Russia
11.15. Saudi Arabia
11.16. South Africa
11.17. Spain
11.18. Sweden
11.19. Switzerland
11.20. Turkey
11.21. United Arab Emirates
11.22. United Kingdom
12. Competitive Landscape
12.1. FPNV Positioning Matrix
12.2. Market Share Analysis, By Key Player
12.3. Competitive Scenario Analysis, By Key Player
13. Competitive Portfolio
13.1. Key Company Profiles
13.1.1. Abbott Laboratories Inc.
13.1.2. AstraZeneca PLC
13.1.3. Bayer AG
13.1.4. Beckman Coulter, Inc.
13.1.5. Bikal Ltd.
13.1.6. CSL Behring LLC
13.1.7. Eli Lilly and Company
13.1.8. Farmson Pharmaceutical Gujarat Pvt. Ltd
13.1.9. GlaxoSmithKline PLC
13.1.10. Glenmark Pharmaceuticals Ltd
13.1.11. Johnson and Johnson
13.1.12. Lonza Group AG
13.1.13. Novartis AG
13.1.14. Pfizer, Inc.
13.1.15. Rhombus Pharma Private Limited
13.1.16. Röchling Group
13.1.17. SCHOTT AG
13.1.18. Sun Pharmaceutical Industries Ltd.
13.1.19. The RSA Group
13.1.20. ZIM Laboratories Limited
13.2. Key Product Portfolio
14. Appendix
14.1. Discussion Guide
14.2. License & Pricing
FIGURE 1. PHARMERGING MARKET RESEARCH PROCESS
FIGURE 2. PHARMERGING MARKET SIZE, 2023 VS 2030
FIGURE 3. PHARMERGING MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 4. PHARMERGING MARKET SIZE, BY REGION, 2023 VS 2030 (%)
FIGURE 5. PHARMERGING MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 6. PHARMERGING MARKET DYNAMICS
FIGURE 7. PHARMERGING MARKET SIZE, BY PRODUCT, 2023 VS 2030 (%)
FIGURE 8. PHARMERGING MARKET SIZE, BY PRODUCT, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 9. PHARMERGING MARKET SIZE, BY INDICATION, 2023 VS 2030 (%)
FIGURE 10. PHARMERGING MARKET SIZE, BY INDICATION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 11. PHARMERGING MARKET SIZE, BY DISTRIBUTION, 2023 VS 2030 (%)
FIGURE 12. PHARMERGING MARKET SIZE, BY DISTRIBUTION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 13. AMERICAS PHARMERGING MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 14. AMERICAS PHARMERGING MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 15. UNITED STATES PHARMERGING MARKET SIZE, BY STATE, 2023 VS 2030 (%)
FIGURE 16. UNITED STATES PHARMERGING MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 17. ASIA-PACIFIC PHARMERGING MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 18. ASIA-PACIFIC PHARMERGING MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 19. EUROPE, MIDDLE EAST & AFRICA PHARMERGING MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 20. EUROPE, MIDDLE EAST & AFRICA PHARMERGING MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 21. PHARMERGING MARKET, FPNV POSITIONING MATRIX, 2023
FIGURE 22. PHARMERGING MARKET SHARE, BY KEY PLAYER, 2023

Pricing

Currency Rates
How Do Licenses Work?

How Do Licenses Work?

The primary function of a report license is to define how many people within a company are authorized to use the purchased report. This is separate to how a report might be delivered. Unless specifically identified otherwise, the purchase option is Single User. Below is a helpful description of that license, along with a sampling of others most commonly offered.

  • This license allows only one user to have access to and to use/read the report. It is not one user at a time or one user group; it is an individual who will be reading and utilizing the report.

  • This license allows for the entire purchasing company to read and use the report. This is the license level that would allow for a report to be placed on an internal company shared drive for access by all employees of that direct company. This license does not extend to parent or sister company use.

  • This license is designed to allow an entire department within a company full access to a report. The departmental license is a great option for companies that have more than one location and the department is spread out all over the country/world

  • This license is for companies that have one location where they want the report to be accessible by all employees within that physical location.

  • This is the most flexible of the licensing options. Some publishers will allow you to get a license for a preset number of people (typically 5). These licenses are ideal for small work groups.

License options are at the discretion of each publisher. As such, not all licenses indicated above are available for every product. If you are uncertain of the best license for your needs or would like a license that is not proactively available, please contact us and we will be happy to assist.

Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
Chat Now
Contact Us